on the drug’s risks, benefits, or optimal use.

Risk Evaluation and Mitigation Strategies (REMS): REMS are required when FDA determines that special strategies are necessary to ensure the benefits of a drug outweigh its risks.

Safety Reporting: Sponsors must report adverse events, medication errors, and serious risks to the FDA through MedWatch and FAERS databases.

Labeling Updates: Changes to product labeling based on new safety or efficacy data must be submitted promptly via FDA Form 2253.

Submission of Annual Reports: Required under 21 CFR 314.81, sponsors must provide updates on ongoing studies, safety, manufacturing changes, and marketing status.

Post-Marketing Commitments (PMCs) vs Requirements (PMRs):

Criteria	PMRs	PMCs
Legally Required?	Yes	No
Enforceable by FDA?	Yes	No
Imposed Under Specific Authority?	Yes (FDAAA, accelerated approval)	Voluntary or suggested by FDA

REMS: Elements to Assure Safe Use (ETASU)

REMS may include one or more of the following elements:

• Healthcare provider certification
• Restricted dispensing through certified pharmacies
• Patient enrollment in registry
• Specific laboratory monitoring requirements

REMS programs are subject to periodic assessment and modification based on new data or safety profiles.

Safety Reporting Requirements:

As part of pharmacovigilance, sponsors must comply with the following:

• 15-day “Alert Reports”: For serious, unexpected adverse drug experiences
• Periodic Safety Update Reports (PSURs): Submitted every 6 months to 1 year depending on the risk classification
• MedWatch Reports: Filed electronically through Form FDA 3500A

Labeling Changes and FDA Form 2253:

Any updates to prescribing information, patient information leaflets, or medication guides must be submitted via FDA Form 2253. Sponsors are required to notify the agency of:

• New contraindications or warnings
• Dosage adjustments based on post-market data
• Safety-related labeling changes

Annual Report Submissions:

These reports include:

• Summary of significant safety findings
• Status of PMRs and PMCs
• Changes in manufacturing processes
• Marketing status in U.S. and other countries

Reports must be submitted within 60 days of the U.S. approval anniversary each year.

Best Practices for Post-Marketing Compliance:

1. Maintain updated Pharma SOPs for pharmacovigilance and safety reporting
2. Implement rigorous GMP documentation controls for manufacturing changes
3. Regularly audit REMS components for compliance
4. Monitor FDA updates and enforce internal SOP changes accordingly
5. Maintain strong collaborations with safety teams, CROs, and regulatory authorities

Consequences of Noncompliance:

• Warning letters and untitled letters
• Civil monetary penalties
• Product withdrawal from the market
• Loss of exclusivity or marketing rights
• FDA inspections and 483 observations

Global Perspective and Integration:

U.S. FDA’s post-marketing surveillance model is increasingly aligned with international authorities like EMA and CDSCO. Collaborative frameworks such as ICH E2E guidelines on pharmacovigilance harmonize safety obligations globally.

Conclusion:

Post-marketing requirements under FDA authority are vital to ensuring long-term drug safety and therapeutic integrity. Sponsors must adopt a proactive compliance framework involving real-time monitoring, documentation, and reporting to remain audit-ready and fulfill their regulatory responsibilities. With evolving regulatory expectations, continuous education and robust systems are key to success in the post-approval landscape.